Lung cancer at the intensive care unit: The era of targeted therapy

Adam, Valerie; Dooms, Christophe; Vansteenkiste, Johan

doi:10.1016/j.lungcan.2015.05.009

Cited by 24 publications

(14 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Many case reports or small case series describing successful critical care treatment of patients with malignancies illustrate how multidisciplinary management that makes use of the full spectrum of modern intensive care and experimental therapeutic approaches can be a lifesaving strategy in selected patients with cancer who are critically ill . Although many problems that are encountered in critically ill patients with cancer also apply to patients without cancer, this patient population has specific characteristics and needs.…”

Section: Evolution Of Critical Care For Patients With Cancermentioning

confidence: 99%

“…22 A growing number of studies demonstrate that seriously ill patients with cancer can benefit from intensive care treatment. 23,24 Many case reports or small case series describing successful critical care treatment of patients with malignancies illustrate how multidisciplinary management that makes use of the full spectrum of modern intensive care and experimental therapeutic approaches can be a lifesaving strategy in selected patients with cancer who are critically ill. [25][26][27][28][29][30] Although many problems that are encountered in critically ill patients with cancer also apply to patients without cancer, this patient population has specific characteristics and needs. Critically ill patients with cancer can present with a variety of cancer-specific complications and conditions, such as leukostasis, superior vena cava syndrome, or paraneoplastic autoimmune phenomena.…”

Section: Evolution Of Critical Care For Patients With Cancermentioning

confidence: 99%

See 1 more Smart Citation

Critical care of patients with cancer

Shimabukuro‐Vornhagen

Böll

Kochanek

et al. 2016

CA A Cancer J Clinicians

112

View full text Add to dashboard Cite

Answer questions and earn CME/CNE The increasing prevalence of patients living with cancer in conjunction with the rapid progress in cancer therapy will lead to a growing number of patients with cancer who will require intensive care treatment. Fortunately, the development of more effective oncologic therapies, advances in critical care, and improvements in patient selection have led to an increased survival of critically ill patients with cancer. As a consequence, critical care has become an important cornerstone in the continuum of modern cancer care. Although, in many aspects, critical care for patients with cancer does not differ from intensive care for other seriously ill patients, there are several challenging issues that are unique to this patient population and require special knowledge and skills. The optimal management of critically ill patients with cancer necessitates expertise in oncology, critical care, and palliative medicine. Cancer specialists therefore have to be familiar with key principles of intensive care for critically ill patients with cancer. This review provides an overview of the state-of-the-art in the individualized management of critically ill patients with cancer. CA Cancer J Clin 2016. © 2016 American Cancer Society.

show abstract

Section: Evolution Of Critical Care For Patients With Cancermentioning

confidence: 99%

Section: Evolution Of Critical Care For Patients With Cancermentioning

confidence: 99%

Critical care of patients with cancer

Shimabukuro‐Vornhagen

Böll

Kochanek

et al. 2016

CA A Cancer J Clinicians

112

View full text Add to dashboard Cite

show abstract

“…Adequate procedures, such as interpreting and periodically summarising the available information, should be evaluated. ECRO will employ the following methods to attain its objectives (box 1): 12 ; the occurrence and causes of excessive delays in starting treatment in cancer patients due to centralised molecular testing [13][14][15] ; the broadening of eligibility inclusion criteria in clinical trials, to avoid disparities in care [16][17][18] ; the consequences of outsourcing the monitoring of trials 7 ; the need to simplify informed consents 11 and so on. 3.…”

Section: Esmo Survey On the Administrative And Bureaucratic Burden Inmentioning

confidence: 99%

ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

Perez-Gracia¹,

Awada

Calvo

et al. 2020

ESMO Open

View full text Add to dashboard Cite

show abstract

“…Chemotherapy requires patient's PS ≥2 while ESMO guidelines state that NSCLC patients with EGFR mutation and PS 3-4 may also be treated with an EGFR TKI (13). Bosch-Barrera (14) and Adam (15) reported that critical lung cancer patients in ICU treated with targeted agents can also get astonishing clinical benefits. Targeted therapy has higher efficacy compared with chemotherapy for patients who have driver gene mutations in key positions (9,16).…”

Section: A B C D E Fmentioning

confidence: 99%

Rapid response in a critical lung adenocarcinoma presenting as large airway stenoses after receiving stent implantation and sequential rebiopsy guided ALK inhibitor therapy: a case report

et al. 2017

View full text Add to dashboard Cite

Airway stent implantation can improve the symptoms of airway stenosis caused by a malignant tumor immediately. However, stent implantation is only a palliative therapy and disease will quickly progress without subsequent treatment. Targeted therapy can provide accurate etiological treatment for patients with critical lung cancer who cannot receive chemotherapies. In our clinic, we encountered a 50-year-old male presenting with stage IV lung adenocarcinoma. He failed both the first-line and second-line chemotherapies and suffered severe complex left and right main bronchial stenoses caused by tumor invasion. An emergency stent was implanted to relieve dyspnea symptoms. At nearly the same time, he was detected to have an ALK gene fusion mutation upon rebiopsy and subsequently began crizotinib therapy. A short time later his obstructed airway returned to normal and lesions in the lung were miraculously reduced. This case indicates that the combination of stent implantation and real-time rebiopsy guided targeted therapy brings a new hope for patients with critical lung cancer. J Thorac Dis 2017;9(3):E230-E235 jtd.amegroups.com in another hospital. His biopsy specimen was acquired by TBNA and ALK status was detected by means of Ventana immunohistochemistry (IHC). He had received five cycles of combination chemotherapies containing carboplatin and pemetrexed and three cycles of combination chemotherapies containing gemcitabine and nedaplatin in that hospital. On arrival (D0), he was in respiratory distress with a respiratory rate of 28 bpm and oxygen saturation of 88-89% without oxygen inhalation. Physical examination was remarkable for scattered rhonchi and decreased breath sounds over both the lung fields. His performance status (PS) was grade 4 (Zubrod-ECOG-WHO score). A chest CT scan at the local hospital showed that the primary lesion had become lager, exacerbating both left and right main bronchial stenoses.Six days later, on D6, he underwent interventional therapy through flexible bronchoscope (FB) (Figure 1). We observed a large new lesion in the carina which was a typical aspect of the invasion of the two main stems bronchi from the mediastinum by the invasion of International Association for the Study of Lung Cancer (IASLC) lymph node station 7. The right main bronchus was completely occluded. We used argon plasma coagulation (APC) to treat the bleeding in the right main bronchus and rebiopsied the neoplasm in the left main bronchus. The neoplasm was then taken for pathologic examination and mutational analyses were completed for EGFR, ALK and ROS1 genes. On D10, under local anaesthesia, he was examined by FB again. We could see the left main bronchial stenosis was slightly relieved while right main bronchus was still obstructed by tumor tissue. We inserted a stent in the left main bronchus through the work way of FB and under its direct vision. When the airway stent was released, we adjusted its position with biopsy forceps and then dilated the airway with a balloon catheter. At last, the stent op...

show abstract

Lung cancer at the intensive care unit: The era of targeted therapy

Cited by 24 publications

References 15 publications

Critical care of patients with cancer

Critical care of patients with cancer

ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy

Rapid response in a critical lung adenocarcinoma presenting as large airway stenoses after receiving stent implantation and sequential rebiopsy guided ALK inhibitor therapy: a case report

Contact Info

Product

Resources

About